Szempliński, S.; Kamecki, H.; Dębowska, M.; Zagożdżon, B.; Mokrzyś, M.; Zawadzki, M.; Sosnowski, R.; Tokarczyk, A.; Poletajew, S.; Kryst, P.;
et al. Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate. J. Clin. Med. 2023, 12, 156.
https://doi.org/10.3390/jcm12010156
AMA Style
Szempliński S, Kamecki H, Dębowska M, Zagożdżon B, Mokrzyś M, Zawadzki M, Sosnowski R, Tokarczyk A, Poletajew S, Kryst P,
et al. Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate. Journal of Clinical Medicine. 2023; 12(1):156.
https://doi.org/10.3390/jcm12010156
Chicago/Turabian Style
Szempliński, Stanisław, Hubert Kamecki, Małgorzata Dębowska, Bartłomiej Zagożdżon, Mateusz Mokrzyś, Marek Zawadzki, Roman Sosnowski, Andrzej Tokarczyk, Sławomir Poletajew, Piotr Kryst,
and et al. 2023. "Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate" Journal of Clinical Medicine 12, no. 1: 156.
https://doi.org/10.3390/jcm12010156
APA Style
Szempliński, S., Kamecki, H., Dębowska, M., Zagożdżon, B., Mokrzyś, M., Zawadzki, M., Sosnowski, R., Tokarczyk, A., Poletajew, S., Kryst, P., & Nyk, Ł.
(2023). Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate. Journal of Clinical Medicine, 12(1), 156.
https://doi.org/10.3390/jcm12010156
